Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia

References

• Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7:11.
   PubMed Web of Science ®Google Scholar
• Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92:548–551.
   Web of Science ®Google Scholar
• Hu Y, Deng H, Huang L, et al. Analysis of Characteristics in Death Patients with COVID-19 Pneumonia without Underlying Diseases. Acad Radiol. 2020;27:752.
   Web of Science ®Google Scholar
• Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020;47:1275–1280.
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38:337–342.
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Fischer a. Connective tissue disease-associated interstitial lung disease. J Intensive Care Med. 2015;30:392–400.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Prim. 2017;3:17074.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
   PubMed Web of Science ®Google Scholar
• Goh KJ, Choong MC, Cheong EH, et al. Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from COVID-19 infection. Ann Acad Med Singapore. 2020;49:1–9.
   Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020 Mar 13:nwaa041.
   Web of Science ®Google Scholar
• Dai H, Zhang X, Xia J, et al. High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China. Int J Infect Dis. 2020;95:106–112.
   PubMed Web of Science ®Google Scholar
• Salehi S, Abedi a, Balakrishnan S, et al. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Am J Roentgenol. 2020:1–7. DOI:10.2214/AJR.20.23672
   Web of Science ®Google Scholar
• Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20:425–434.
   PubMed Web of Science ®Google Scholar
• Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:372.
   PubMed Web of Science ®Google Scholar
• Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10:102–108.
   PubMed Web of Science ®Google Scholar
• Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020:NEJMoa2020283. DOI:10.1056/NEJMoa2020283
   Web of Science ®Google Scholar
• Godri Pollitt KJ, Peccia J, Ko AI, et al. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission. Hum Genomics. 2020;14:17.
   PubMed Web of Science ®Google Scholar
• Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11:29.
   PubMed Web of Science ®Google Scholar
• Sallenave J-M, Guillot L. Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: key therapeutic targets? Front Immunol. 2020;11:1229.
   PubMed Web of Science ®Google Scholar
• Olejnik J, Hume AJ, Mühlberger E. Toll-like receptor 4 in acute viral infection: too much of a good thing. PLoS Pathog. 2018;14:1–7.
   Web of Science ®Google Scholar
• Pierer M, Wagner U, Rossol M, et al. Toll-like receptor 4 is involved in inflammatory and joint destructive pathways in collagen-induced arthritis in DBA1j mice. PLoS One. 2011;6:8–13.
   Web of Science ®Google Scholar
• Bhattacharyya S, Wang W, Qin W, et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight. 2018;3:1–17.
   Web of Science ®Google Scholar
• Papanikolaou IC, Boki KA, Giamarellos-Bourboulis EJ, et al. Innate immunity alterations in idiopathic interstitial pneumonias and rheumatoid arthritis-associated interstitial lung diseases. Immunol Lett. 2015;163:179–186.
   PubMed Web of Science ®Google Scholar
• Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol. 2012;12:295–305.
   PubMed Web of Science ®Google Scholar
• Whitfield SJC, Taylor C, Risdall JE, et al. Interference of the T cell and antigen-presenting cell costimulatory pathway using CTLA4-Ig (Abatacept) prevents staphylococcal enterotoxin B pathology. J Immunol. 2017;198:3989–3998.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Cantaert T, Atkins SR, et al. Summary for Policymakers. In: Intergovernmental Panel on Climate Change, editor. Clim. Chang. 2013 - Phys. Sci. Basis. 3rd ed. Cambridge: Cambridge University Press; 2017. p. 1–30.
   Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529–539.
   PubMed Web of Science ®Google Scholar
• Younan P, Ramanathan P, Graber J, et al. The toll-like receptor 4 antagonist eritoran protects mice from lethal filovirus challenge. Vogel SN, Patton JT, editors. MBio. 2017;8. DOI:10.1128/mBio.00226-17
   Web of Science ®Google Scholar
• Marr N, Turvey SE. Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication. Innate Immun. 2012;18:856–865.
   PubMed Web of Science ®Google Scholar
• Kuzmich N, Sivak K, Chubarev V, et al. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines (Basel). 2017;5:34.
   PubMed Web of Science ®Google Scholar
• Shi H, Han X, Cao Y, et al. CT screening for early diagnosis of SARS-CoV-2 infection – authors’ reply. Lancet Infect Dis. 2020;3099:20200229.
   Google Scholar
• Zheng Q, Lu Y, Lure F, et al. Clinical and radiological features of novel coronavirus pneumonia. J Xray Sci Technol. 2020;28:391–404.
   PubMed Web of Science ®Google Scholar
• George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020. DOI:10.1016/S2213-2600(20)30225-3.
   Web of Science ®Google Scholar
• Karampitsakos T, Woolard T, Bouros D, et al. Toll-like receptors in the pathogenesis of pulmonary fibrosis. Eur J Pharmacol. 2017;808:35–43.
   PubMed Web of Science ®Google Scholar
• Ebener S, Barnowski S, Wotzkow C, et al. Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF. Am J Physiol - Lung Cell Mol Physiol. 2017;312:L42–L55.
   PubMed Web of Science ®Google Scholar
• Go H, Koh J, Kim HS, et al. Expression of toll-like receptor 2 and 4 is increased in the respiratory epithelial cells of chronic idiopathic interstitial pneumonia patients. Respir Med. 2014;108:783–792.
   PubMed Web of Science ®Google Scholar
• Yang H-Z, Wang J-P, Mi S, et al. TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury. Am J Pathol. 2012;180:275–292.
   PubMed Web of Science ®Google Scholar
• Yang H-Z, Cui B, Liu H-Z, et al. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol. 2009;182:692–702.
   PubMed Web of Science ®Google Scholar
• Zhao H, Leu S-W, Shi L, et al. TLR4 is a negative regulator in noninfectious lung inflammation. J Immunol. 2010;184:5308–5314.
   PubMed Web of Science ®Google Scholar
• He Z, Zhu Y, Jiang H. Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fibrosis during acute lung injury induced by lipopolysaccharide: an experimental study. Respir Res. 2009;10:126.
   PubMed Web of Science ®Google Scholar
• He Z, Gao Y, Deng Y, et al. Lipopolysaccharide induces lung fibroblast proliferation through toll-like receptor 4 signaling and the phosphoinositide3-kinase-akt pathway. Sanchez-Margalet V, editor. PLoS One. 2012;7:e35926.
   PubMed Web of Science ®Google Scholar
• Noth I, Zhang Y, Ma S-F, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1:309–317.
   PubMed Web of Science ®Google Scholar
• Doz E, Noulin N, Boichot E, et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol. 2008;180:1169–1178.
   PubMed Web of Science ®Google Scholar
• Tao L, Yang J, Cao F, et al. Mogroside IIIE, a novel anti-fibrotic compound, reduces pulmonary fibrosis through toll-like receptor 4 pathways. J Pharmacol Exp Ther. 2017;361:268–279.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Kelley K, Melichian DS, et al. Toll-like receptor 4 signaling augments transforming growth factor-β responses. Am J Pathol. 2013;182:192–205.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Tamaki Z, Wang W, et al. FibronectinEDA promotes chronic cutaneous fibrosis through toll-like receptor signaling. Sci Transl Med. 2014;6:232ra50–232ra50.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Asano Y, Ichimura Y, et al. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheumatol. 2015;67:254–265.
   PubMed Web of Science ®Google Scholar
• Saigusa R, Asano Y, Taniguchi T, et al. Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis. Proc Natl Acad Sci. 2015;112:15136–15141.
   PubMed Web of Science ®Google Scholar
• Balbir-Gurman a, Guralnik L, Yigla M, et al. Imaging aspects of interstitial lung disease in patients with rheumatoid arthritis: literature review. Autoimmun Rev. 2018;17:87–93.
   PubMed Web of Science ®Google Scholar
• Cassone G, Manfredi a, Vacchi C, et al. Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. JCM. 2020;9:1082.
   Web of Science ®Google Scholar
• Brito Y, Glassberg MK, Ascherman DP. Rheumatoid arthritis-associated interstitial lung disease: current concepts. Curr Rheumatol Rep. 2017;19. DOI:10.1007/s11926-017-0701-5
   PubMed Web of Science ®Google Scholar
• Samarpita S, Kim JY, Rasool MK, et al. Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug. Arthritis Res Ther. 2020;22:1–10.
   PubMed Web of Science ®Google Scholar
• Teoh AKY, Corte TJ. Nonspecific interstitial pneumonia. Semin Respir Crit Care Med. 2020;41:184–201.
   PubMed Web of Science ®Google Scholar
• Yoshinouchi T, Naniwa T, Shimizu S, et al. Expression of chemokine receptors CXCR3 and CCR4 in lymphocytes of idiopathic nonspecific interstitial pneumonia. Respir Med. 2007;101:1258–1264.
   PubMed Web of Science ®Google Scholar
• Sacre SM, Drexler SK, Andreakos E, et al. Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann Rheum Dis. 2007;66:81–86.
   PubMed Web of Science ®Google Scholar
• Monnet E, Choy EH, McInnes I, et al. Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. Ann Rheum Dis. 2020;79:316–323.
   PubMed Web of Science ®Google Scholar
• Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43:613–626.
   PubMed Web of Science ®Google Scholar
• Schwind LTF, Arrieira RL, Dias JD, et al. The structure of planktonic communities of testate amoebae (Arcellinida and uglyphida) in three environments of the Upper Paraná River basin, Brazil. J Limnol. 2016;75:78–89.
   Web of Science ®Google Scholar
• Manfredi a, Cassone G, Furini F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study. Intern Med J. 2019:imj.14670. DOI:10.1111/imj.14670
   Web of Science ®Google Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri a, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020. DOI:10.1016/S2665-9913(20)30173-9.
   Google Scholar
• Boleto G, Guignabert C, Pezet S, et al. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. Arthritis Res Ther. 2018;20:197.
   PubMed Web of Science ®Google Scholar
• Jiménez-Alvarez L, Arreola JL, Ramírez-Martínez G, et al. The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis. Exp Mol Pathol. 2011;91:718–722.
   PubMed Web of Science ®Google Scholar
• Fernández-Díaz C, Loricera J, Castañeda S, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum. 2018;48:22–27.
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Ikari K, Yano K, et al. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept. Mod Rheumatol. 2019;29:413–417.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013;40:787–797.
   PubMed Web of Science ®Google Scholar
• Wenink MH, Santegoets KCM, Platt AM, et al. Abatacept modulates proinflammatory macrophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation. Ann Rheum Dis. 2012;71:80–83.
   PubMed Web of Science ®Google Scholar
• Ferro F, Elefante E, Baldini C, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020;38:175–180.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis an international working group report. Am J Respir Crit Care Med. 2016;194:265–275.
   PubMed Web of Science ®Google Scholar
• Manfredi a, Sebastiani M, Cerri S, et al. Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. J Thorac Dis. 2019;11:1621–1628.
   PubMed Web of Science ®Google Scholar
• Johannson KA, Vittinghoff E, Lee K, et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. 2014;43:1124–1131.
   PubMed Web of Science ®Google Scholar
• Cheung O-Y, Graziano P, Smith ML. Acute lung injury. In: Pract. Pulm. Pathol. a Diagnostic Approach. 3rd ed. Elsevier; 2018. p. 125–146.e3.
   Google Scholar
• Schupp JC, Binder H, Jäger B, et al. Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. PLoS One. 2015;10:1–11.
   Web of Science ®Google Scholar
• Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 2007;30:835–839.
   PubMed Web of Science ®Google Scholar
• Yildizhan E, Kaynar L. Cytokine release syndrome. J Oncol Sci. 2018;4:134–141.
   Google Scholar
• Rooney C, Sauer T. Modeling cytokine release syndrome. Nat Med. 2018;24:705–706.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195. iagnosis-and-management.
   PubMed Web of Science ®Google Scholar
• Ishikawa G, Acquah SO, Salvatore M, et al. Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease. Respir Med. 2017;128:78–84.
   PubMed Web of Science ®Google Scholar
• Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475–1482.
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Azuma a, Inoue Y, et al. Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2020;201:1110–1119.
   Google Scholar
• Kubo H, Yanai M, Azuma A. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup? Am J Respir Crit Care Med. 2013;187(9):1029–1030.
   PubMed Web of Science ®Google Scholar
• Noth I, Olman M. Reply: a placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup? Am J Respir Crit Care Med. 2013;187:1030.
   PubMed Web of Science ®Google Scholar
• Mora AL, Torres-González E, Rojas M, et al. Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol. 2006;35:466–473.
   PubMed Web of Science ®Google Scholar
• Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604.
   PubMed Web of Science ®Google Scholar
• Kolb M, Margetts PJ, Anthony DC, et al. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest. 2001;107:1529–1536.
   PubMed Web of Science ®Google Scholar
• Ganter MT, Roux J, Miyazawa B, et al. Interleukin-1β causes acute lung injury via αvβ5 and αvβ6 integrin–dependent mechanisms. Circ Res. 2008;102:804–812.
   PubMed Web of Science ®Google Scholar
• Osterholzer JJ, Olszewski MA, Murdock BJ, et al. Implicating exudate macrophages and Ly-6C high monocytes in CCR2-dependent lung fibrosis following gene-targeted alveolar injury. J Immunol. 2013;190:3447–3457.
   PubMed Web of Science ®Google Scholar
• Brieland JK, Flory CM, Jones ML, et al. Regulation of monocyte chemoattractant protein-1 gene expression and secretion in rat pulmonary alveolar macrophages by lipopolysaccharide, tumor necrosis factor-alpha, and interleukin-1 beta. Am J Respir Cell Mol Biol. 1995;12:104–109.
   PubMed Web of Science ®Google Scholar
• Rodenburg RJT, Brinkhuis RFB, Peek R, et al. Expression of macrophage-derived chemokine (MDC) mRNA in macrophages is enhanced by interleukin-1 β, tumor necrosis factor α, and lipopolysaccharide. J Leukoc Biol. 1998;63:606–611.
   PubMed Web of Science ®Google Scholar
• Ren YH, Wang SY, Liu M, et al. When COVID-19 encounters interstitial lung disease: challenges and management. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E039.
   Google Scholar
• Sallenave JM, Guillot L. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets? Front Immunol. 2020;11:1229
   Google Scholar
• Papiris SA, Tomos IP, Karakatsani a, et al. High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations. Cytokine. 2018;102:168–172.
   PubMed Web of Science ®Google Scholar
• Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Cell Mol Physiol. 2010;299:L3–L7.
   PubMed Web of Science ®Google Scholar
• Enomoto N, Oyama Y, Enomoto Y, et al. Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis. Clin Respir J. 2018;12:2378–2389.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Günther a, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost. 2000;83:853–860.
   PubMed Web of Science ®Google Scholar
• Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med. 2003;31:S213–S220.
   PubMed Web of Science ®Google Scholar
• Frantzeskaki F, Armaganidis a, Orfanos SE. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation. Respiration. 2017;93:212–225.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104–107.
   PubMed Web of Science ®Google Scholar
• Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34–45.
   PubMed Web of Science ®Google Scholar
• van der Poll T, Herwald H. The coagulation system and its function in early immune defense. Thromb Haemost. 2014;112:640–648.
   PubMed Web of Science ®Google Scholar
• Schulz C, Engelmann B, Massberg S. Crossroads of coagulation and innate immunity: the case of deep vein thrombosis. J Thromb Haemost. 2013;11(Suppl 1):233–241.
   PubMed Web of Science ®Google Scholar
• Maniatis NA, Kotanidou a, Catravas JD, et al. Endothelial pathomechanisms in acute lung injury. Vascul Pharmacol. 2008;49:119–133.
   PubMed Web of Science ®Google Scholar
• Ramirez GA, Rovere-Querini P, Sabbadini M, et al. Parietal and intravascular innate mechanisms of vascular inflammation. Arthritis Res Ther. 2015;17:16.
   PubMed Web of Science ®Google Scholar
• Tomashefski JF, Davies P, Boggis C, et al. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol. 1983;112:112–126.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382:e38.
   PubMed Web of Science ®Google Scholar
• Greene R, Zapol WM, Snider MT, et al. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis. 1981;124:593–601.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan a, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–402.
   PubMed Web of Science ®Google Scholar
• Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395:683–684.
   PubMed Web of Science ®Google Scholar
• Fragkou PC, Belhadi D, Peiffer-Smadja N, et al. Review of trials currently testing treatment and prevention of COVID-19. Clin Microbiol Infect. 2020;26:988–998.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Sharif K, O’Regan a, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19:102537.
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31.
   PubMed Web of Science ®Google Scholar
• Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92:814–818.
   Web of Science ®Google Scholar
• Gendelman O, Amital H, Bragazzi NL, et al. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: insights from a large healthcare database analysis. Autoimmun Rev. 2020;19:102566.
   PubMed Web of Science ®Google Scholar
• Vardavas C, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18:1–4.
   Web of Science ®Google Scholar
• Luppi F, Cerri S, Taddei S, et al. Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Intern Emerg Med. 2015;10:401–411.
   PubMed Web of Science ®Google Scholar